Researchers demonstrate that Aeolus Pharmaceuticals' AEOL 10150 protects lungs from chlorine gas

Aeolus Pharmaceuticals, Inc. (OTCBB: AOLS) reported that researchers from National Jewish Health and McGill University have completed a series of preliminary studies demonstrating that AEOL 10150 protects lungs from chlorine gas exposure in mice. There are currently no effective treatments for chlorine gas exposure and AEOL 10150 is a major focus of a sponsored research grant awarded by the NIH CounterAct program to National Jewish Health to identify an effective treatment. Chlorine gas has been used in warfare since World War I and still poses a significant threat to civilian and military personnel, as well as a threat from industrial and transportation accidents. Chlorine gas exposure can cause significant respiratory injury and chemical-induced asthma.

“We are very impressed with the robust effects of AEOL 10150 in rescuing the lung against the deleterious effects of inhaled chlorine gas,” stated Dr. Carl White, pediatric pulmonologist at National Jewish Health and Director of the CounterACT Center of Excellence in Denver. “These data expand our earlier studies where AEOL 10150 protected the lung against mustard gas.”